2nd Ophthalmic Drug Development and Delivery Summit.
The Second Annual Ophthalmic Drug Development and Delivery Summit was held on 19 - 20 September 2006 in San Diego, CA, US. The 2-day symposium, having a highly focused theme, was packed with cutting-edge science, insightful overviews and networking opportunities. With a total of 11 recognized specialists presenting reviews and recent results in the advancement of ocular drug development and delivery, the invited expert speaking faculty presented the latest preclinical and clinical developments in novel ophthalmic therapies and drug delivery technology. The talks included various case studies from primary investigators and pharmaceutical companies touching upon key topics: updates on current clinical trials, study design issues, sustained delivery to the eye, views of the vitreous space as a drug reservoir, new developments in dry and wet age-related macular degeneration and diabetic retinopathy, formulation for optimal drug delivery, differences and similarities in developing drugs for the eye compared with other targets, pharmacokinetics, novel ocular delivery methods and devices, delivery of proteins and peptides, focal drug delivery, non-invasive drug delivery to the eye, neuroprotection challenges, in vitro and in vivo models for glaucoma and angiogenesis for early efficacy estimation, and toxicology. Overall, the 2-day annual symposium continues to grow as an efficient platform for fostering discussion on a range of scientific topics and challenges and avenues for building collaborative partnerships in ophthalmic drug development.
Marra
Michelle
M
Research Formulations, Science & Technology, Pfizer Global R&D, La Jolla Laboratories, Pfizer, Inc., San Diego CA 92121, USA.
Gukasyan
Hovhannes J
HJ
Raghava
Swita
S
Kompella
Uday B
UB
D000818:Animals; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D003930:Diabetic Retinopathy / Q000188:drug therapy; D016503:Drug Delivery Systems / Q000379:methods*; D004343:Drug Implants / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D008266:Macula Lutea; D008268:Macular Degeneration / Q000188:drug therapy; D012164:Retinal Diseases / Q000188:drug therapy* / Q000209:etiology; D015861:Retinal Neovascularization / Q000188:drug therapy; D014822:Vitreous Body / Q000601:surgery
D003692:Delayed-Action Preparations; D004343:Drug Implants